Live feed08:00:00·8mPRReleasevia QuantisnowMirum Pharmaceuticals Announces Primary Endpoint Met in Phase 3 EXPAND Study of LIVMARLI® (maralixibat) in Ultra-Rare Cholestatic Liver DiseasesByQuantisnow·Wall Street's wire, on your screen.MIRM· Mirum Pharmaceuticals Inc.Health Care
